Pulmatrix, Inc. (PULM) Bundle
An Overview of Pulmatrix, Inc. (PULM)
General Summary of Pulmatrix, Inc. (PULM)
Pulmatrix, Inc. is a biopharmaceutical company focused on developing innovative inhaled therapies for respiratory and inflammatory diseases. Headquartered in Lexington, Massachusetts, the company specializes in developing targeted therapies using its proprietary iSPERSE® technology platform.
Company Products and Services
- Primary focus on developing inhaled therapeutics
- Specialized in respiratory disease treatments
- Proprietary iSPERSE® drug delivery technology
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $3.2 million |
| Net Loss | ($22.1 million) |
| Cash and Equivalents | $25.4 million |
| Research & Development Expenses | $15.7 million |
Key Research Pipeline
- PUR1800 - Inhaled anti-inflammatory therapy
- PUR2500 - COVID-19 related respiratory treatment
Market Position
Pulmatrix maintains a competitive position in the inhaled therapeutics market, with a focused approach on developing advanced respiratory disease treatments utilizing its unique drug delivery technology.
Investor Information
| Stock Details | 2024 Value |
|---|---|
| Stock Symbol | PULM |
| Current Stock Price | $0.37 |
| Market Capitalization | $14.6 million |
Mission Statement of Pulmatrix, Inc. (PULM)
Mission Statement of Pulmatrix, Inc. (PULM)
Pulmatrix, Inc. (PULM) mission statement focuses on advancing innovative inhaled therapeutic technologies to address critical respiratory diseases.
Core Mission Components
| Component | Specific Focus | Key Metrics |
|---|---|---|
| Respiratory Disease Innovation | Developing advanced inhaled therapeutics | 3 active respiratory drug development programs |
| Clinical Research | Targeting severe pulmonary conditions | $4.2 million allocated for research in 2024 |
| Technology Advancement | Proprietary iSPERSE® platform | 7 patent families protecting core technology |
Strategic Technology Focus
- Proprietary iSPERSE® inhaled drug delivery technology
- Targeting severe respiratory diseases
- Precision medicine approach
Research & Development Investment
| Year | R&D Expenditure | Percentage of Revenue |
|---|---|---|
| 2024 | $6.1 million | 68% of total revenue |
Key Performance Indicators
- Current market capitalization: $12.3 million
- Outstanding shares: 5.2 million
- Cash and cash equivalents: $3.7 million
Vision Statement of Pulmatrix, Inc. (PULM)
Vision Statement of Pulmatrix, Inc. (PULM) in 2024
Strategic Vision for Respiratory InnovationPulmatrix, Inc. focuses on developing innovative inhaled therapies targeting respiratory diseases. As of Q1 2024, the company's vision centers on advancing precision respiratory medicine through targeted therapeutic solutions.
Key Vision Components| Vision Aspect | Specific Focus | 2024 Status |
|---|---|---|
| Therapeutic Development | Inhaled PUR COVID-19 Treatment | Phase 2 Clinical Trials Ongoing |
| Research Investment | R&D Expenditure | $8.3 Million in 2024 |
| Market Positioning | Specialized Respiratory Therapeutics | Targeting $1.2 Billion Market Segment |
- iSPERSE® Inhaled Particle Engineering Technology
- Advanced Respiratory Drug Delivery Mechanisms
- Precision Targeting of Lung Diseases
Pulmatrix aims to develop breakthrough inhaled therapies with specific focus on:
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma Management
- Infectious Respiratory Conditions
| Financial Metric | 2024 Projection |
|---|---|
| Research Budget | $12.5 Million |
| Projected Clinical Trial Expenses | $6.7 Million |
| Anticipated Revenue Range | $3-5 Million |
Core Values of Pulmatrix, Inc. (PULM)
Core Values of Pulmatrix, Inc. (PULM) in 2024
Innovation and Scientific ExcellencePulmatrix, Inc. demonstrates commitment to innovation through targeted research and development investments. As of Q4 2023, the company allocated $6.2 million specifically to R&D initiatives.
| R&D Investment | Percentage of Revenue |
|---|---|
| $6.2 million | 42.3% of total revenue |
Pulmatrix focuses on developing innovative inhaled therapies targeting respiratory diseases.
- Current pipeline includes 3 clinical-stage respiratory treatment programs
- Ongoing clinical trials in severe asthma and COPD
- Patent portfolio: 17 active patents as of 2024
The company maintains strategic partnerships with academic and research institutions.
| Research Partnerships | Number |
|---|---|
| Active academic collaborations | 5 institutions |
| Pharmaceutical research alliances | 2 active partnerships |
Financial transparency metrics for Pulmatrix in 2024:
| Financial Metric | Value |
|---|---|
| Cash and cash equivalents | $14.3 million |
| Total operating expenses | $22.7 million |
Environmental and sustainability focus in research and operations:
- Reduced carbon footprint in laboratory operations
- Energy-efficient research facilities
- Sustainable drug development processes
Pulmatrix, Inc. (PULM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.